PDVR A 阶段管理:从联合PRP和抗VEGF治疗结果的洞察
Manpreet Brar1, Satinderpal Singh Grewal1, Gagandeep Singh2
1Department of Retina, Grewal Eye Institute, Chandigarh, India.
European journal of ophthalmology
|May 9, 2025
概括
使用泛视网膜光凝血 (PRP) 和抗血管内皮生长因子 (Anti-VEGF) 注射的联合治疗有效地管理早期增殖性糖尿病视网膜病变 (PDVR). 这种方法可以稳定视力,并防止大多数患者需要进行玻璃切除术.
科学领域:
- 眼科医生 眼科 眼科
- 糖尿病视网膜病变 - 糖尿病视网膜病变
- 视网膜疾病 视网膜疾病
背景情况:
- 增殖性糖尿病视网膜病变 (PDVR) 具有显著的视力损失风险.
- 早期的PDVR需要有效的管理,以防止进展.
- 为了改善治疗结果,正在探索组合疗法.
研究的目的:
- 评估联合泛网膜光凝 (PRP) 和抗血管内皮生长因子 (Anti-VEGF) 注射的疗效.
- 评估患有A期多发性糖尿病视网膜病变 (PDVR) 的患者的结果.
- 分析纤维血管扩散的进展,玻璃体出血,新血管化和拉力视网膜脱落.
主要方法:
- 追溯的,非随机的案例系列.
- 包括被诊断患有A期PDVR的患者,接受PRP和Anti-VEGF联合治疗.
- 疾病进展的定性评估和视力敏度变化的定量评估.
主要成果:
- 88.72%的患者表现出疾病的消失或稳定.
- 从基线 (0.5) 到6个月 (0.32) 的改善logMAR最佳校正视觉敏度.
- 观察到最小的进展:20.8%经历了玻璃体增殖引的恶化,12.5%在6个月后重新生长了新血管.
结论:
- 联合PRP和Anti-VEGF疗法有效控制早期PDVR.
- 这种治疗策略可以稳定视力,并可能避免玻璃切除术.
- 建议进行长期研究,以确认持续的疗效和安全性.
关键词:
糖尿病视网膜病变 - 糖尿病视网膜病变这是bevacizumab的治疗方法.摄影凝固是指光凝固的过程.拉尼比祖马布拉尼尼比祖马布拉尼视网膜 视网膜 视网膜 是一个视网膜脱落 视网膜脱落 视网膜脱落视网膜新血管化疗法玻璃体出血的发生更多相关视频
09:46Isolation, Culture, and Genetic Engineering of Mammalian Primary Pigment Epithelial Cells for Non-Viral Gene Therapy
Published on: February 26, 2021
3.1K
13:48Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
Published on: April 21, 2023
1.3K
相关概念视频
01:24Parkinson's Disease: Treatment
154
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
154
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
101
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
101